Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Blood Component Removal × Clear all

Phase

Phase 2 12 Phase 1 10 Phase 1/2 6 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cisplatin 598 Carboplatin 497 Paclitaxel 481 Cyclophosphamide 443 Radiotherapy 440 Docetaxel 405 Fluorouracil 373 Gemcitabine 356 Doxorubicin 337 Capecitabine 307 Dexamethasone 276 Oxaliplatin 239 Vincristine 231 pembrolizumab 228 Leucovorin 227 Etoposide 225 Bevacizumab 225 Rituximab 204 Prednisone 193 Pemetrexed 178 Cytarabine 176 Drug Therapy 167 Trastuzumab 146 Methotrexate 146 Irinotecan 136 Lenalidomide 120 Filgrastim 115 Nivolumab 111 Chemotherapy, Adjuvant 109 Tamoxifen 105

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02489500 2018-09-10

VelRand

Boston Medical Center

Phase 3 Terminated

3 enrolled 11 charts

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡